Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France.

Autor: Decarreaux D; Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France.; INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, France.; Unité des Virus Emergents, Aix Marseille University, IRD 190, INSERM U1207, 13005 Marseille, France., Pouquet M; INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, France., Souty C; INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, France., Vilcu AM; INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, France., Prévot-Monsacre P; INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, France., Fourié T; Unité des Virus Emergents, Aix Marseille University, IRD 190, INSERM U1207, 13005 Marseille, France., Villarroel PMS; Unité des Virus Emergents, Aix Marseille University, IRD 190, INSERM U1207, 13005 Marseille, France., Priet S; Unité des Virus Emergents, Aix Marseille University, IRD 190, INSERM U1207, 13005 Marseille, France., Blanché H; Fondation Jean Dausset-CEPH, 75000 Paris, France., Sebaoun JM; Fondation Jean Dausset-CEPH, 75000 Paris, France., Deleuze JF; Fondation Jean Dausset-CEPH, 75000 Paris, France., Turbelin C; INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, France., Werner A; Association Française de Pédiatrie Ambulatoire (AFPA), 69000 Orléans, France., Kochert F; Association Française de Pédiatrie Ambulatoire (AFPA), 69000 Orléans, France., Grosgogeat B; Faculté d'Odontologie, Université Claude Bernard Lyon 1, Université de Lyon, 69000 Lyon, France.; Laboratoire des Multimatériaux et Interfaces, UMR CNRS 5615, Université Claude Bernard Lyon 1, Université de Lyon, 69000 Lyon, France.; Réseau ReCOL, Association Dentaire Française, 75000 Paris, France.; Service d'Odontologie, Hospices Civils de Lyon, 69007 Lyon, France., Rabiega P; IQVIA, Réseau de Pharmaciens, 75000 Paris, France., Laupie J; Réseau ReCOL, Association Dentaire Française, 75000 Paris, France., Abraham N; IQVIA, Réseau de Pharmaciens, 75000 Paris, France., Guerrisi C; INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, France., Noël H; Infectious Diseases Division, Santé Publique France, 94410 Saint Maurice, France., Van der Werf S; Institut Pasteur, Université Paris Cité, CNRS UMR3569, Molecular Genetics of RNA Viruses Unit, 75015 Paris, France.; Institut Pasteur, Université Paris Cité, National Reference Center for Respiratory Viruses, 75015 Paris, France., Carrat F; INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, France.; Département de Santé Publique, Hôpital Saint-Antoine, APHP, 75012 Paris, France., Hanslik T; INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, France.; Faculty of Health Sciences Simone Veil, Université de Versailles Saint-Quentin-en-Yvelines, UVSQ, UFR de Médecine, 78000 Versailles, France.; Service de Médecine Interne, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris (APHP), 92100 Boulogne Billancourt, France., Charrel R; Unité des Virus Emergents, Aix Marseille University, IRD 190, INSERM U1207, 13005 Marseille, France., De Lamballerie X; Unité des Virus Emergents, Aix Marseille University, IRD 190, INSERM U1207, 13005 Marseille, France., Blanchon T; INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP), Sorbonne Université, 75012 Paris, France., Falchi A; Laboratoire de Virologie, Université de Corse Pascal Paoli, UR7310 Bioscope, 20250 Corte, France.
Jazyk: angličtina
Zdroj: Viruses [Viruses] 2022 May 03; Vol. 14 (5). Date of Electronic Publication: 2022 May 03.
DOI: 10.3390/v14050957
Abstrakt: We aimed to investigate the immunoglobulin G response and neutralizing activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) among primary health care workers (PHCW) in France and assess the association between the neutralizing activity and several factors, including the coronavirus disease 2019 (COVID-19) vaccination scheme. A cross-sectional survey was conducted between 10 May 2021 and 31 August 2021. Participants underwent capillary blood sampling and completed a questionnaire. Sera were tested for the presence of antibodies against the nucleocapsid (N) protein and the S-1 portion of the spike (S) protein and neutralizing antibodies. In total, 1612 PHCW were included. The overall seroprevalences were: 23.6% (95% confidence interval (CI) 21.6-25.7%) for antibodies against the N protein, 94.7% (93.6-95.7%) for antibodies against the S protein, and 81.3% (79.4-83.2%) for neutralizing antibodies. Multivariate regression analyses showed that detection of neutralizing antibodies was significantly more likely in PHCW with previous SARS-CoV-2 infection than in those with no such history among the unvaccinated (odds ratio (OR) 16.57, 95% CI 5.96-59.36) and those vaccinated with one vaccine dose (OR 41.66, 95% CI 16.05-120.78). Among PHCW vaccinated with two vaccine doses, the detection of neutralizing antibodies was not significantly associated with previous SARS-CoV-2 infection (OR 1.31, 95% CI 0.86-2.07), but was more likely in those that received their second vaccine dose within the three months before study entry than in those vaccinated more than three months earlier (OR 5.28, 95% CI 3.51-8.23). This study highlights that previous SARS-CoV-2 infection and the time since vaccination should be considered when planning booster doses and the design of COVID-19 vaccine strategies.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje